Zobrazeno 1 - 10
of 47 118
pro vyhledávání: ''
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Publikováno v:
Cancer Research and Treatment. 54:680-689
PurposeThe current study aimed to identify the overall characteristics of cancer-related emergency department (ED) visits by adult in Korea, including analyses of factors associated with ED stay time and outcomes nationwide. Materials and MethodsWe c
Publikováno v:
Clinical Lung Cancer. 23:e118-e130
To evaluate postoperative outcome and quality of life (QOL), comparing patients80 years old to patients ≥ 80.EORTC questionnaires, QLQ-C30 and QLQ-LC13 was used to assess QOL, in patients after surgery. Results were evaluated according to 3 age gro
Autor:
Charles Coutant, Catherine Loustalot, Marie-Martine Padeano, Laura Vincent, Aurélie Bertaut, Hélène Costaz, K. Peignaux, M. Rouffiac, Isabelle Desmoulins, Delphine Boulle, Clémentine Jankowski, Françoise Beltjens, Sylvain Causeret, Laurent Arnould, Sylvain Ladoire
Publikováno v:
Bulletin du Cancer. 109:268-279
Summary Purpose In the ACOSOG Z0011 trial, patients with primary breast cancer and 1–2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), d
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a